HUMA — Completion of Humacyte Human Acellular Vessel Clinical Trial
Sep 1, 2027, 4:00:00 AM UTC
Summary
Humacyte, Inc. announced the expected completion of its Human Acellular Vessel (HAV) clinical trial for patients with vascular trauma on September 1, 2027. This multicenter, non-randomized phase 2 study involves up to 40 adult patients who require surgical repair for life- or limb-threatening vascular trauma. Participants will receive an HAV as an interposition vessel or bypass in surgical procedures. The trial, which began on September 1, 2018, has an overall status of active but not recruiting, with an anticipated total duration of 61 months for all participants. The findings may impact the company's therapeutic portfolio and market positioning in vascular repair solutions.
Company
HUMACYTE INC (HUMA)NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
www.humacyte.comSimilar Events
Clinical Trial Completion for Auryon Atherectomy System
Angiodynamics, Inc. is conducting a clinical trial to evaluate the Auryon Atherectomy System against standard balloon angioplasty. The trial is expected to complete on April 1, 2029, and will include approximately 200 participants. The study, currently in Phase 4, aims to enhance treatment options for patients with vascular disease. The company intends to recruit up to 1500 subjects overall, allowing some inclusion in an observational study for those not qualifying for randomized trials. This trial may have implications for the company's product portfolio and market position in the vascular therapy space.
Clinical Trial CompletionCompletion of Clinical Trial for AllogeneiC Expanded Human MSC Therapy
BioCardia, Inc. is set to complete its clinical trial of the AllogeneiC Expanded Human MSC Therapy, a treatment utilizing allogeneic bone marrow-derived mesenchymal stem cells, in patients recovering from COVID-19 Acute Respiratory Distress, on December 1, 2025. This investigational therapy aims to determine the safety and optimal dosing of NK1R+ hMSC in addressing inflammation-mediated lung injury, a serious complication in severe COVID-19 cases. The trial is not yet recruiting and the company is expected to begin enrollment in August 2024.
clinical trial completionCompletion of CYC140 Clinical Trial
Cyclacel Pharmaceuticals, Inc. is expected to complete its clinical trial investigating CYC140 in subjects with advanced solid tumors and lymphoma by November 1, 2025. The trial includes a Phase 1 dose-escalation and dose-finding component, followed by a Phase 2 segment enrolling around 330 patients with various advanced cancers, including bladder cancer, triple-negative breast cancer, and metastatic colorectal cancer. The study aims to provide treatment options for patients who have failed standard therapies or for whom no standard therapies are available, potentially advancing cancer treatment strategies.
Clinical TrialCompletion of Hybrid Therapy and Heart Team for Atrial Fibrillation Clinical Trial
The Hybrid Therapy and Heart Team for Atrial Fibrillation clinical trial is expected to complete on December 31, 2025. Sponsored by University Hospital in Toulouse, the trial addresses atrial fibrillation (AF), the most common cardiac arrhythmia, associated with increased risks of heart failure and stroke. The trial explores the effectiveness of hybrid therapy, which combines surgical and catheter techniques, over traditional catheter ablation methods. Hybrid therapy aims for higher success rates in restoring sinus rhythm while avoiding incomplete lesions and pulmonary vein isolation. The trial has enrolled 228 participants to date, and is currently in the recruiting phase.
clinical trial completion